EGFR and head and neck squamous cell carcinoma: In the last decade, cetuximab, an anti-EGFR human-mouse chimeric IgG1 monoclonal antibody (mAb) was approved by the Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and HNSCC patients (28, 29).